Work

Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.

Year: 2005

Type: letter

Abstract: The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented. HU controls thrombocytosis both in polycythemia vera (PV) and in essential thrombocythemia (ET), while reducing the risk of thrombosis.1 Despite many anectodal reports, no evaluation of the prevalence and type of side effects of HU exists in large series of patients.

Source: PubMed

Authors: Maria Luigia Randi, Elisabetta Ruzzon, Guido Luzzatto, Fabiana Tezza, Antonio Girolami, Fabrizio Fabris

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2217750424

Cites: 10

Cited by: 33

Related to: 10